Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | TSHR | P16473 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.65 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.65 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.52 |
| ▸ | CDK8 | P49336 | 1/20 | 0.52 |
| ▸ | NEK2 | P51955 | 1/20 | 0.52 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.52 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.52 |
| ▸ | STAT3 | P40763 | 1/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30737629 | 1.00 | MEN1 (0.66) | MEN1TSHRKMT2AKEAP1NFE2L2 | |
| SCHEMBL7589375 | 0.87 | MEN1 (0.77) | MEN1TSHRKMT2AKEAP1NFE2L2 | |
| SCHEMBL2068236 | 0.85 | ALDH1A1 (0.58) | MEN1KMT2AKEAP1PKMGLO1 | |
| SCHEMBL30737452 | 0.85 | ALDH1A1 (0.58) | MEN1KMT2AKEAP1PKMGLO1 | |
| Hydrochloric Acid SCHEMBL29885455 | 0.84 | ALDH1A1 (0.56) | MEN1KMT2AKEAP1PKMGLO1 | |
| SCHEMBL30737499 | 0.83 | ALDH1A1 (0.66) | MEN1TSHRKMT2A | |
| SCHEMBL398000 | 0.83 | LMNA (0.70) | MEN1TSHRKMT2AKEAP1NFE2L2 | |
| SCHEMBL15145878 | 0.83 | MEN1 (0.52) | MEN1KMT2AL3MBTL1 | |
| SCHEMBL4184006 | 0.83 | ALDH1A1 (0.66) | MEN1TSHRKMT2A | |
| SCHEMBL7854392 | 0.82 | TSHR (0.70) | MEN1TSHRKMT2AKEAP1NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117510460-A | Benzo [ b ] thiophene derivative containing sulfonamide unit, and preparation method and application thereof | 贵州大学 | 2024-02-06 | — | — | CN | disclosed |
| US-9216954-B2 | Serine racemase inhibitor | NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (JP) | 2015-12-22 | — | — | US | disclosed |
| US-9216954-B2 | Serine racemase inhibitor | NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (JP) | 2015-12-22 | — | — | US | disclosed |
| US-20140371291-A1 | SERINE RACEMASE INHIBITOR | NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (JP) | 2014-12-18 | — | — | US | disclosed |
| US-20140371291-A1 | SERINE RACEMASE INHIBITOR | NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (JP) | 2014-12-18 | — | — | US | disclosed |
| EP-2808014-A1 | SERINE RACEMASE INHIBITOR | National University Corporation University Of Toyama (JP) | 2014-12-03 | — | — | EP | disclosed |
| EP-2808014-A1 | SERINE RACEMASE INHIBITOR | National University Corporation University Of Toyama (JP) | 2014-12-03 | — | — | EP | disclosed |
| WO-2013111798-A1 | SERINE RACEMASE INHIBITOR | 国立大学法人 富山大学 (JP) | 2013-08-01 | — | — | WO | disclosed |
| EP-0990645-B1 | NOVEL SULFONAMIDE DERIVATIVES | NIPPON KAYAKU KK (JP) | 2004-07-28 | — | — | EP | disclosed |
| US-6458960-B1 | ANTICANCER AGENTS, RHEUMATIC DISEASES AND ANTIINFLAMMATORY AGENTS | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2002-10-01 | — | — | US | disclosed |
| US-6180796-B1 | TUBULIN POLYMERIZATION INHIBITORS | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2001-01-30 | — | — | US | disclosed |
| EP-0990645-A1 | NOVEL SULFONAMIDE DERIVATIVES | Nippon Kayaku Kabushiki Kaisha (JP) | 2000-04-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371291-A1 | SERINE RACEMASE INHIBITOR | SRR, PRSS1, ME1 | MEN1 1089/4885TSHR 4233/4885KMT2A 3922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.